| Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer F Rojo, J Garcia-Parra, S Zazo, I Tusquets, J Ferrer-Lozano, S Menendez, ... Annals of oncology 23 (5), 1156-1164, 2012 | 216 | 2012 |
| Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial JM Pérez-García, M Vaz Batista, P Cortez, M Ruiz-Borrego, JM Cejalvo, ... Neuro-oncology 25 (1), 157-166, 2023 | 153 | 2023 |
| Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study D Prieto-Alhambra, MK Javaid, S Servitja, NK Arden, M Martinez-García, ... Breast cancer research and treatment 125, 869-878, 2011 | 123 | 2011 |
| NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival A Muntasell, F Rojo, S Servitja, C Rubio-Perez, M Cabo, D Tamborero, ... Clinical Cancer Research 25 (5), 1535-1545, 2019 | 107 | 2019 |
| Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program X Castells, L Domingo, JM Corominas, I Torá-Rocamora, MJ Quintana, ... Breast cancer research and treatment 149, 237-244, 2015 | 99 | 2015 |
| Interplay between natural killer cells and anti-HER2 antibodies: perspectives for breast cancer immunotherapy A Muntasell, M Cabo, S Servitja, I Tusquets, M Martínez-García, A Rovira, ... Frontiers in immunology 8, 1544, 2017 | 89 | 2017 |
| Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer MA Sabbaghi, G Gil-Gómez, C Guardia, S Servitja, O Arpí, ... Clinical Cancer Research 23 (22), 7006-7019, 2017 | 88 | 2017 |
| Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain L Domingo, M Sala, S Servitja, JM Corominas, F Ferrer, J Martínez, ... Cancer Causes & Control 21, 1155-1164, 2010 | 81 | 2010 |
| Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor–positive, ERBB2-negative advanced breast cancer: a randomized … A Llombart-Cussac, JM Pérez-García, M Bellet, F Dalenc, M Gil-Gil, ... JAMA oncology 7 (12), 1791-1799, 2021 | 76 | 2021 |
| Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin F Rojo, I González-Navarrete, R Bragado, A Dalmases, S Menéndez, ... Clinical Cancer Research 15 (10), 3530-3539, 2009 | 75 | 2009 |
| Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the … M Martín, A Ruiz, MR Borrego, A Barnadas, S González, L Calvo, MM Vila, ... Journal of clinical oncology 31 (20), 2593-2599, 2013 | 69 | 2013 |
| Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer X Nogues, S Servitja, MJ Peña, D Prieto-Alhambra, R Nadal, ... Maturitas 66 (3), 291-297, 2010 | 68 | 2010 |
| Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer S Servitja, X Nogués, D Prieto-Alhambra, M Martínez-García, L Garrigós, ... The Breast 21 (1), 95-101, 2012 | 64 | 2012 |
| Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study N Garcia-Giralt, M Rodríguez-Sanz, D Prieto-Alhambra, S Servitja, ... Breast cancer research and treatment 140, 385-395, 2013 | 61 | 2013 |
| SEOM clinical guidelines in early stage breast cancer (2018) F aYaLa dE La PEña, R Andrés, JA Garcia-Saenz, L Manso, M Margelí, ... Clinical and Translational Oncology 21, 18-30, 2019 | 59 | 2019 |
| Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers L Domingo, J Blanch, S Servitja, JM Corominas, C Murta-Nascimento, ... European journal of cancer prevention 22 (1), 21-28, 2013 | 57 | 2013 |
| Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles J Bayo, PJ Fonseca, S Hernando, S Servitja, A Calvo, S Falagan, ... Clinical and Translational Oncology 14, 413-422, 2012 | 56 | 2012 |
| Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer A Dalmases, I González, S Menendez, O Arpí, JM Corominas, S Servitja, ... Oncotarget 5 (1), 196, 2014 | 52 | 2014 |
| Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study D Prieto-Alhambra, S Servitja, MK Javaid, L Garrigós, NK Arden, ... Breast cancer research and treatment 133, 1159-1167, 2012 | 50 | 2012 |
| Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain I Esteban, M Vilaró, E Adrover, A Angulo, E Carrasco, N Gadea, ... Psycho‐Oncology 27 (6), 1530-1537, 2018 | 45 | 2018 |
